Mathilde/NLI4PR huggingface dataset:
Patient case (clinical description): A 19-year-old male came to clinic with some sexual concern.  He recently engaged in a relationship and is worried about the satisfaction of his girlfriend. He has a "baby face" according to his girlfriend's statement and he is not as muscular as his classmates.  On physical examination, there is some pubic hair and poorly developed secondary sexual characteristics. He is unable to detect coffee smell during the examination, but the visual acuity is normal. Ultrasound reveals the testes volume of 1-2 ml. The hormonal evaluation showed serum testosterone level of 65 ng/dL with low levels of GnRH.

Patient's own account: I'm 19 years old guy and I just went to see a doctor at the clinic after I just got with my girlfriend. I'm kinda worried because she thinks that I have a baby face and to be honest, I'm way less muscular than my classmates. I don't have much hair down there, and yes, I don't have that macho look. The doctor made me smell some coffee and I couldn't smell anything special. I also had some eyesight checkups and the doctor told me everything was normal. I got my test results back and it says: testes volume is 1-2 ml and serum testosterone level of 65 ng/dL with low GnRH levels.

Clinical trial: Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men

Eligibility criteria:
Inclusion Criteria:

          -  A confirmed diagnosis of secondary hypogonadism

          -  Mild to moderate erectile dysfunction

          -  Ability to read, understand and complete diaries and questionnaires

          -  Ability to safely make sexual attempts during the course of the study

        Exclusion Criteria:

          -  Primary hypogonadism

          -  Hypogonadism as a result of surgery, trauma, tumors or radiation of the hypothalamus
             or pituitary

          -  History or current diagnosis of breast cancer, prostate cancer and/or PSA level above
             ≥3.5 ng/mL

          -  Poorly controlled blood pressure, type 2 diabetes, thyroid disease; sleep apnea

          -  Elevated prolactin level

          -  Hemoglobin >17 g/dL or Hematocrit >50%

          -  Use of transdermal or oral testosterone within 4 weeks, intramuscular testosterone
             therapy within 6 weeks, and testosterone pellets within 6 months prior to Screening
             and at any time throughout the study

          -  Use of another SERM or past participation in a trial with Fispemifene

          -  Use of medications known to alter the HPG axis

          -  Clinically significant findings on physical exam, screening labs, or other findings
             which would prevent safe participation in the study

          -  Participation in another clinical study in the last 30 days
Male
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 64 Years

Eligibility (NLI label): Contradiction
Patient case (clinical description): A 49-year-old man comes to the office because of the bulging in his groin.  Physical examination shows a swelling above the inguinal ligament. When the patient is asked to cough, the size of the bulge increases.  His medical history is significant for mild dyslipidemia, which is under control by lifestyle modifications. He does not smoke, but drinks alcohol occasionally. His vital signs and other physical examinations are unremarkable. He is referred to a surgeon and scheduled to undergo elective laparoscopic hernia repair.

Patient's own account: I'm a 49-year-old man and I went to my doctor the other day because I could not stand that sharp pain in my upper thigh, it was so swollen! The doctor told me that it was swollen right next to my ligament. It's even bigger when I'm coughing. I'm suffering from high cholesterol and I already had to adapt my lifestyle to keep the disease under control. I do not smoke but to be honest I still drink from time to time. The doctor found my vitals normal. She gave me a note to see a surgeon to get my mass removed and get a hernia repair.

Clinical trial: Desarda Repair for Inguinal Hernia

Eligibility criteria:
Inclusion Criteria:

          -  inguinal hernia

        Exclusion Criteria:

          -  recurrent inguinal hernia

          -  giant inguinal hernia

          -  mental disorder

          -  refusal to participate
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Eligibility (NLI label): Entailment
Patient case (clinical description): A 20-year-old man comes to the emergency due to bleeding after a tooth extraction.  The bleeding has persisted for approximately 30 minutes despite constant direct pressure.  He is a known case of Hemophilia type A treated with FVIII. Blood pressure is 95/60 mm Hg and pulse is 105/min. His weight is 70 Kg. Family history is positive for Hemophilia type A in his maternal uncle. He also has a lipoma on his left arm which he plans to remove surgically. His FVIII activity is 40%.

Patient's own account: I got my tooth extracted and I could not stop bleeding for 30 min. I'm a 20 yo dude but I have Hemophilia type A treated with FVIII. My blood pressure was 95/60 and my pulse 105/min. I'm 70 kg. My uncle on my mom's side also has type A hemophilia. I also have a fatty swelling on my left arm and I was supposed to remove it. My FVIII activity was 40%.

Clinical trial: The Hemophilia Inhibitor Prevention Trial

Eligibility criteria:
Inclusion Criteria:

          1. Male children >= 4 months and up to 4 years of age.

          2. Severe hemophilia A (FVIII < 0.01 U/ml).

          3. No evidence of an inhibitor i.e. anti-FVIII < 0.6 B.U.

          4. No more than 3 FVIII exposures (Factor VIII concentrate, cryoprecipitate, or fresh
             frozen plasma), including circumcision.

        Exclusion Criteria:

          1. Acquired hemophilia or any bleeding disorder other than hemophilia A.

          2. Treatment with clotting factor or emicizumab previously.

          3. Use of an experimental drug(s).

          4. Surgery anticipated in the next 48 weeks.

          5. Life expectancy less than 5 years.

          6. Parent/caretaker unable or unwilling to keep a personal diary of bleeding frequency
             and study drug treatment, make monthly visits and blood draws at weeks 4, 12, 24, 36,
             and 48.

          7. Other illness, condition or reason in the opinion of the investigator that would make
             the patient unsuitable for the trial.
Male
No healthy subjects accepted to join the trial.
Subject must be at least 4 Months old.
Subject must be at most 4 Years

Eligibility (NLI label): Entailment
Patient case (clinical description): A 19-year-old male came to clinic with some sexual concern.  He recently engaged in a relationship and is worried about the satisfaction of his girlfriend. He has a "baby face" according to his girlfriend's statement and he is not as muscular as his classmates.  On physical examination, there is some pubic hair and poorly developed secondary sexual characteristics. He is unable to detect coffee smell during the examination, but the visual acuity is normal. Ultrasound reveals the testes volume of 1-2 ml. The hormonal evaluation showed serum testosterone level of 65 ng/dL with low levels of GnRH.

Patient's own account: I'm 19 years old guy and I just went to see a doctor at the clinic after I just got with my girlfriend. I'm kinda worried because she thinks that I have a baby face and to be honest, I'm way less muscular than my classmates. I don't have much hair down there, and yes, I don't have that macho look. The doctor made me smell some coffee and I couldn't smell anything special. I also had some eyesight checkups and the doctor told me everything was normal. I got my test results back and it says: testes volume is 1-2 ml and serum testosterone level of 65 ng/dL with low GnRH levels.

Clinical trial: Pharmacokinetic Study of Testosterone Enanthate

Eligibility criteria:
Inclusion Criteria:

          -  Adult males aged 18 to 75 with a documented diagnosis of hypogonadism

        Exclusion Criteria:

          -  Normal testosterone levels

          -  Subjects with any clinically significant medical condition which, in the opinion of
             the Investigator, would make the subject an unsuitable candidate for enrollment in the
             study
Male
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 75 Years

Eligibility (NLI label): Entailment
Patient case (clinical description): A 19-year-old male came to clinic with some sexual concern.  He recently engaged in a relationship and is worried about the satisfaction of his girlfriend. He has a "baby face" according to his girlfriend's statement and he is not as muscular as his classmates.  On physical examination, there is some pubic hair and poorly developed secondary sexual characteristics. He is unable to detect coffee smell during the examination, but the visual acuity is normal. Ultrasound reveals the testes volume of 1-2 ml. The hormonal evaluation showed serum testosterone level of 65 ng/dL with low levels of GnRH.

Patient's own account: I'm 19 years old guy and I just went to see a doctor at the clinic after I just got with my girlfriend. I'm kinda worried because she thinks that I have a baby face and to be honest, I'm way less muscular than my classmates. I don't have much hair down there, and yes, I don't have that macho look. The doctor made me smell some coffee and I couldn't smell anything special. I also had some eyesight checkups and the doctor told me everything was normal. I got my test results back and it says: testes volume is 1-2 ml and serum testosterone level of 65 ng/dL with low GnRH levels.

Clinical trial: Bone Mineral Markers in Hypogonadism

Eligibility criteria:
Inclusion Criteria:

          -  male patients with hypogonadotropic hypogonadism

          -  being under the age of 45 and over the age of 18

          -  not previously given testosterone or human chorionic gonadotropin therapy

          -  not have any chronic metabolic disorders or organ dysfunction

        Exclusion Criteria:

          -  female patients

          -  Other reasons hipogondism

          -  receive any treatment of hypogonadism

          -  presence of comorbid diseases
Male
Accepts Healthy Volunteers
Subject must be at least 18 Years old.
Subject must be at most 45 Years

Eligibility (NLI label): Entailment
Patient case (clinical description): A 23-year-old man comes to the emergency department following an episode of syncope.  He was working out when he felt dizzy and passed out without head injury.  He has had 3 other episodes of light-headedness over the last year, all happening during physical activity. He never had this experience while resting. He has no other medical conditions.  The patient does not use tobacco, alcohol, or illicit drugs.  His father died suddenly at age 35.  Vital signs are within normal limits.  On physical examination, the patient has a harsh systolic murmur.  The lungs are clear with no peripheral edema. Echocardiography shows asymmetric interventricular septal hypertrophy.

Patient's own account: I'm 23, and I got admitted to the ER because I fainted all of a sudden. I was in the gym, working out, when all of a sudden, I just got dizzy and passed out. Hopefully, I didn't hit my head. It's not my first time having that kind of dizziness at the gym, never when I'm chilling at home tho. I don't have any special medical conditions and I'm not even smoking, drinking or doing drugs! My dad died suddenly when he was 35, so I'm kind of scared. My vitals were normal while at the ER and they did a physical exam and they told me my heart sounds abnormal. My lungs are ok, but I had to do an echography of my heart, and they told me it is bigger than average.

Clinical trial: Surgical Septal Myectomy vs Percutaneous Transluminal Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy

Eligibility criteria:
Inclusion Criteria:

          1. Age between 40-75 years including 40 and 75 years of age

          2. HOCM eligible for both SSM and ASA by a heart team (multidisciplinary team) and core
             lab.

          3. Left ventricle outflow tract (LVOT) obstruction > 30mmHg at rest or during
             physiological provocation by transthoracic echocardiogram

          4. Symptomatic (New York Heart Association classification (NYHA) >1 or Canadian
             Cardiovascular Society (CCS) class >1) and/or syncope due to HOCM

        Exclusion Criteria:

          1. Unable to give informed consent

          2. A life expectancy of less than 1 year

          3. Concomitant (structural valve disease, aorta, rhythm, CABG) surgery during the same
             session

          4. Not able to perform bicycle ergometry exercise test
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 40 Years old.
Subject must be at most 75 Years

Eligibility (NLI label): Contradiction
Patient case (clinical description): A 20-year-old man comes to the emergency due to bleeding after a tooth extraction.  The bleeding has persisted for approximately 30 minutes despite constant direct pressure.  He is a known case of Hemophilia type A treated with FVIII. Blood pressure is 95/60 mm Hg and pulse is 105/min. His weight is 70 Kg. Family history is positive for Hemophilia type A in his maternal uncle. He also has a lipoma on his left arm which he plans to remove surgically. His FVIII activity is 40%.

Patient's own account: I got my tooth extracted and I could not stop bleeding for 30 min. I'm a 20 yo dude but I have Hemophilia type A treated with FVIII. My blood pressure was 95/60 and my pulse 105/min. I'm 70 kg. My uncle on my mom's side also has type A hemophilia. I also have a fatty swelling on my left arm and I was supposed to remove it. My FVIII activity was 40%.

Clinical trial: Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A

Eligibility criteria:
Inclusion criteria :

          -  Participant must be younger than 12 years of age, at the time of signing the informed
             consent

          -  Severe hemophilia A defined as <1 IU/dL (<1%) endogenous FVIII as documented either by
             central laboratory testing at Screening or in historical medical records from a
             clinical laboratory demonstrating <1% FVIII coagulant activity (FVIII:C) or a
             documented genotype known to produce severe hemophilia A.

          -  Previous treatment for hemophilia A (prophylaxis or on-demand) with any recombinant
             and/or plasma-derived FVIII, or cryoprecipitate for at least 150 EDs for patients aged
             6-11 years and above 50 EDs for patients aged <6 years

          -  Weight above or equal to 10 kg.

        Exclusion criteria:

          -  History of hypersensitivity or anaphylaxis associated with any FVIII product.

          -  History of a positive inhibitor (to FVIII) test defined as ≥0.6 BU/mL, or any value
             greater than or equal to the lower sensitivity cut-off for laboratories with cut-offs
             for inhibitor detection between 0.7 and 1.0 BU/mL, or clinical signs or symptoms of
             decreased response to FVIII administrations. Family history of inhibitors will not
             exclude the participant.

          -  Positive inhibitor test result, defined as ≥0.6 BU/mL at Screening.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Male
No healthy subjects accepted to join the trial.

Subject must be at most 12 Years

Eligibility (NLI label): Contradiction
Patient case (clinical description): A 23-year-old woman comes to the emergency department with a history of nosebleeds lasting for 1 hour. She has a history of heavy menses as well as occasional gum bleeding following dental procedures. Her mother also has a history of menorrhagia. Laboratory tests reveal increased bleeding time and slightly increased partial thromboplastin time. She has no other medical conditions and is otherwise healthy. Her coagulation study shows CB = 0.30 IU/mL and FVIII:C = 0.37 IU/mL. She is not smoking or using any kind of illicit drugs. She uses alcohol occasionally and is in ra elationship with her boyfriend for the past 2 years.

Patient's own account: I had to rush to the ER because of a non-stop nosebleed that had been on for 1 hour. As a 23-year-old, I always had heavy periods, and sometimes, my gums would bleed after going to the dentist or brushing my teeth. I thought that it was not very alarming since my mom also had heavy periods. I did some lab tests that showed that I had increased bleeding time and long clotting time. Otherwise, I'm pretty healthy, and I don't smoke or take any kind of drugs. I drink only at parties from time to time. I have been with my boyfriend for the last 2 years. I did a coagulation study and I got the following results: CB = 0.30 IU/mL and FVIII:C = 0.37 IU/mL.

Clinical trial: Xylitol Chewing-gums: Concentration in Saliva and Antibacterial Effect

Eligibility criteria:
Inclusion Criteria:

          -  good general health,

          -  the absence of diseases that can alter the saliva secretion rate

          -  a stimulated saliva flow at least of 1 ml/min.

        Exclusion Criteria:

        -
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 19 Years old.
Subject must be at most 26 Years

Eligibility (NLI label): Entailment
Patient case (clinical description): An 8-year-old boy is brought to the clinic by his parents because of weakness and difficulty of standing up from a sitting position. The mother is healthy but had a brother who died in his 20th after being disabled and using wheelchairs in the last few years of his life. Physical examination shows 3/5 lower extremity muscle strength and enlarged calf muscles. The other physical examination and vital signs are unremarkable. Muscle biopsy showed absence of dystrophin protein. The patient is diagnosed with DMD.

Patient's own account: I brought my  8-year-old son to the doctor's clinic. He was struggling to stand up from a chair for the past few days. My wife is healthy but she was pretty worried since his brother died in his 20s after being disabled and using a wheelchair for the last years of his life. The doctor did an exam which highlighted weakness in the leg muscles and unusually large calf muscles. The rest of the exam was fine, and his vitals were normal. My son did a muscle biopsy, and it showed that the protein important for muscle strength and function is missing. The doctor diagnosed him with Duchenne muscular dystrophy.

Clinical trial: Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Eligibility criteria:
Inclusion Criteria:

          1. Patient has completed the NS-065/NCNP-01-301 study;

          2. Patient's parent(s) or legal guardian(s) has (have) provided written informed consent
             and Health Insurance Portability and Accountability Act authorization, where
             applicable, prior to any study-related procedures; patients will be asked to give
             written or verbal assent according to local requirements;

          3. Patient and parent(s)/guardian(s) are willing and able to comply with scheduled
             visits, investigational product (IP) administration plan, and study procedures.

        Exclusion Criteria:

          1. Patient had an adverse event in Study NS-065/NCNP-01-301 that, in the opinion of the
             investigator and/or the sponsor, precludes safe use of viltolarsen for the patient in
             this study;

          2. Patient had a treatment which was made for the purpose of dystrophin or
             dystrophin-related protein induction after completion of Study NS-065/NCNP-01-301;

          3. Patient took any other investigational drug(s) during or after completion of Study
             NS-065/NCNP-01-301;

          4. Patient is judged by the investigator and/or the sponsor not to be appropriate to
             participate in the extension study for any reason.
Male
No healthy subjects accepted to join the trial.



Eligibility (NLI label): Contradiction
Patient case (clinical description): A 63-year-old man comes to the clinic for recent unintentional weight loss. The patient also has epigastric discomfort after meals. He has no known medical problems and takes no medications. His blood pressure is 130/75 and pulse rate is 88/min. He is not febrile. Upper endoscopy shows a lesion in the stomach that shows typical features of diffuse-type adenocarcinoma presenting with signet ring cells that do not form glands.

Patient's own account: I went to the clinic because I had been losing so much weight that it was concerning. I'm a 63-year-old guy, and it is something rather unusual. I'm always suffering from stomachache after every meal. I've never been sick, and I don't take any medicine. The doctor took my blood pressure and told me it was 130/75, and my pulse rate was 88/min. I'm not febrile! I also had to do an endoscopy, and they found a lesion in my stomach that shows typical features of stomach cancer. I'm totally devastated...

Clinical trial: The Role of 68Ga-FAPI-04 PET/CT as a Problem Solving Imaging Modality in Various Malignancies

Eligibility criteria:
Inclusion Criteria:

        The study population will include up to 50 patients with disease in whom a diagnostic
        challenge is met, including but not limited to:

          1. Inconclusive findings on 18F-FDG PET/CT or other imaging modalities.

          2. Better delineation of tumor extent prior to therapy

          3. Malignancies known to show variable avidity to FDG and at times, no uptake at all
             (e.g. Exocrine Pancreatic cancer, Gastric carcinoma, Mucin-producing or Signet-ring
             carcinoma).

          4. Patients unable to optimally comply with the required preparation for FDG imaging.

               -  The study population will include only patients treated in Tel-Aviv Sourasky
                  Medical Center, Tel-Aviv, Israel, and referred by their attending physicians, of
                  whom are part of the hospital staff.

        Exclusion Criteria:

          -  Age < 18 years.

          -  Pregnant females.

          -  Patients who are reluctant to undergo both FDG and FAPI PET scans.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 120 Years

Eligibility (NLI label): Entailment